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The severe DowlingMeara form of epidermolysis bullosa simplex is caused by dominant-negative mutations in
keratins 5 and 14, which are speciﬁcally expressed in the basal keratinocytes of the epidermis. The most common
mutation in the DowlingMeara form of epidermolysis bullosa simplex patients is the missense mutation R125C in
exon 1 of the K14 gene. We made a primary keratinocyte cell line from a sporadic case known to carry the R125C
mutation as part of an ongoing gene therapy initiative. The full-length K14 cDNA was sequenced using keratinocyte
mRNA. Unexpectedly, a second mutation was identiﬁed in K14: a heterozygous 1 bp insertion mutation (242insG)
upstream of the R125C mutation. This frameshift mutation creates a premature termination codon immediately
downstream, thereby nullifying the dominant-negative allele. The second mutation was only present in DNA derived
from keratinocytes and was absent from lymphocyte DNA. This case represents a novel mechanism of revertant
mosaicism and is an example of ‘‘natural gene therapy’’.
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Epidermolysis bullosa simplex (EBS) is an inherited skin
disorder characterized by intraepidermal blistering due to
cytolysis in the subnuclear region of the basal keratino-
cytes. There are three main clinical subtypes: EBS Dow-
lingMeara (EBS-DM; OMIM 131760), EBS WeberCockayne
(OMIM 131800), and EBS Ko¨bner (OMIM131900) (Fine et al,
1991; Fine et al, 2000). Most are inherited in an autosomal
dominant manner and many cases are sporadic. EBS-DM is
considered the most severe form, with widespread blister-
ing occurring from birth. Blisters occur in herpetiform
clusters on the trunk and proximal extremities and heal
with minor scarring. Nails may be dystrophic and there is
often progressive hyperkeratosis of the palms and soles.
Histologically, abnormal clumping of keratin filaments is
seen within the basal keratinocytes of EBS-DM patients
(Anton-Lamprecht and Schnyder, 1982; Ishida-Yamamoto
et al, 1991; McGrath et al, 1992).
During the last decade it has been demonstrated that
type I and type II keratins form a dynamic structural
cytoskeleton within all epithelial cells. One line of evidence
for this has come from the identification of mutations in
different keratin genes, all of which produce a skin fragility
phenotype (Irvine and McLean, 1999; Porter and Lane,
2003). In general these are dominant-acting mutations and
lead to disruption of the keratin cytoskeleton. EBS is caused
by mutations in the basal cell keratins 5 and 14 leading to
cell fragility and skin blistering in response to mild physical
trauma. In EBS-DM patients the most common mutation is
the heterozygous missense K14 mutation R125C, located in
the helix initiation motif in the helix 1 A domain of the K14
polypeptide (Smith, 2003).
Now that the molecular basis of EBS and of many other
keratin disorders is known the current focus of research is
treatment and prevention of these disorders. As the majority
of keratin mutations act in a dominant-negative manner,
treatment in the form of gene therapy requires inactivation
of the mutant gene. Therapeutic strategies are currently
being developed but must be tested in model systems, such
as cell culture, before progressing to clinical trials. Recen-
tly, a transgenic mouse has been developed that provides a
realistic model of EBS-DM and will provide another system
to test different approaches in vivo (Cao et al, 2001).
We have cultured primary keratinocytes from an EBS-DM
patient known to carry the most common K14 mutation,
R125C, to use for therapy development. Unexpectedly, a
second K14 mutation was identified in these cells: a
heterozygous 1 bp insertion mutation just upstream of the
R125C mutation. This creates a premature termination
codon (PTC) immediately downstream thereby silencing the
dominant-negative R125C mutation. This case represents a
novel mechanism of revertant mosaicism and is an example
of ‘‘natural gene therapy’’, a term originally coined by
Jonkman et al (1997).
Results
Clinical data The patient, a female Scottish Caucasian, a
sporadic case now in her early 20s, suffered from wide-
spread herpetiform blistering since birth, entirely typical of
EBS-DM, as shown in Fig 1. There was keratoderma on the
soles of her feet (Fig 1) and striking postinflammatory
hyperpigmentation at sites of healed blisters. The patient
reported that she had undergone a significant improvement
in the skin blistering phenotype from her early teensAbbreviation: PTC, premature termination codon.
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onwards. Although she suffered from widespread herpeti-
form blisters on the trunk and elsewhere during childhood,
she now gets lesions predominantly on her face, ears, and
neck. These blisters generally cannot be linked to an
obvious frictional event and they tend to lead to recalcitrant,
slow healing lesions. In contrast, she now only rarely gets
blisters on her trunk and when she does, it is in response to
an obvious traumatic incident and these blisters generally
heal quickly. She still suffers from keratoderma; however,
this is only a minor source of discomfort. In order to
establish a primary keratinocyte cell line from the patient, a
4 mm punch biopsy was taken from a nonlesional site on
the lower abdomen. The biopsy site healed quickly and
completely with no occurrence of blistering in that site in the
several months following the biopsy.
Mutation detection Primary keratinocytes were cultured
from a skin biopsy taken from a nonlesional site of an EBS-
DM patient known to have the K14 R125C mutation,
detected originally by analysis of lymphocyte genomic
DNA (E.L. Rugg et al, manuscript in preparation). Surpris-
ingly, staining of the keratinocytes with monoclonal anti-
body LL001 against K14 showed that the majority of cells
had a normal keratin filament network and only a small
percentage of cells had filament aggregates reported to be
associated with this particular mutation (Coulombe et al,
1991) (Fig 2). As a routine check to validate the mutation,
mRNA was extracted from the cells and the full-length K14
cDNA was sequenced. This revealed that the R125C
mutation was barely detectable in keratinocyte cDNA
(Fig 3). The original lymphocyte DNA samples were re-
screened, and in these cells the mutation was present in a
1:1 ratio with the normal allele (Figs 3, 4). A neutral
polymorphism N123N was also barely detectable in
keratinocyte cDNA but easily visible in the lymphocyte
DNA sequence. Furthermore, in the cDNA sequence, very
low levels of overlapping sequence traces could be seen
upstream of the R125C mutation. These overlapping traces
were clearly visible in genomic DNA derived from primary
keratinocytes, however (Fig 4). The overlapping traces were
due to a heterozygous 1 bp insertion mutation, designated
242insG, which was confirmed by cloning the PCR product.
A fragment spanning exon 1 of K14 was PCR amplified from
genomic DNA from cultured keratinocytes and cloned into
the pCR2.1 vector. Clones were sequenced and three types
of clone were identified (Fig 4). These were (1) wild-type
(eight clones); (2) R125C mutation (four clones); and (3)
R125C mutation and 242insG (revertant clone, five clones).
The frameshift mutation 242insG creates a PTC (TAG)
immediately downstream. Because the allele with the
242insG mutation also carries the R125C mutation, the
consequence of this frameshift results not only in a
truncated K14 but also in silencing of the downstream
R125C mutation. The 242insG mutation was completely
absent in lymphocyte DNA. The complete coding sequence
of K14 was sequenced; no other changes were found
except some known polymorphisms in exon 1.
The presence of the 242insG mutation was also shown by
analysis of fluorescently labeled K14 PCR products run on
Figure 1
Clinical features of the patient. (a)–(c) Widespread herpetiform
blistering present since birth. (d) Keratoderma on the soles of the feet.
Figure2
Immunofluorescence staining of primary keratinocytes. Cells were
stained with monoclonal antibody LL001 against K14 (green). Nuclei
were counterstained with DAPI (blue). (a) Control keratinocytes showing
a normal K14 filament network. (b) Patient keratinocytes showing a
normal filament network in the majority of cells and a small percentage
of cells with filament aggregates (arrows).
Figure3
DNA sequencing of patient keratinocyte cDNA compared to
patient lymphocyte DNA showing K14 R125C mutation (reverse
sequence). (a) Patient K14 cDNA sequence corresponding to codons
121–127 (reverse sequence shown here) demonstrating heterozygous
missense mutation 373C4T (arrow) predicting the amino acid change
R125C and heterozygous neutral polymorphism 369C4T (N123N)
(arrow). Note that the R125C mutation is barely visible. (b) The same
region of the K14 gene as shown in (a) but derived from patient
lymphocyte DNA. The R125C mutation (arrow) is present in a 1:1 ratio
with the normal allele.
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an ABI 3100 DNA sequencer (Fig 5). Two peaks were
present in cDNA and genomic K14 PCR products derived
from keratinocytes demonstrating presence of the 1 bp
insertion, 242insG. Only one peak was seen from K14 PCR
products from patient and control lymphocyte DNA.
Comparing the genomic traces to those from RT-PCR
products, the relative amount of the larger allele, as
determined by integration of the peak areas in the
Genotyper program, is reduced by about 37% in the cDNA
sample. Thus, the insertion mutation results in significant
nonsense-mediated mRNA decay as well as truncating the
K14 protein within the V1 domain before expression of
potentially dominant-negative rod domain sequences.
Discussion
Now that many keratin disorders can be diagnosed at the
molecular level, the focus of several research groups is on
developing treatment. Here, we have grown primary
keratinocytes from an EBS-DM patient known to carry the
common K14 mutation, R125C, for use in developing gene
therapy strategies. Unexpectedly during a routine check,
however, we identified a second mutation, 242insG, in
cDNA and genomic DNA derived from primary keratino-
cytes. Cloning of the keratinocyte genomic PCR products
revealed that the R125C allele also carried the 242insG
frameshift. This insertion mutation is just upstream of
R125C and creates a PTC immediately downstream thereby
nullifying the R125C mutation. The resulting truncated K14
Figure 4
DNA sequencing of patient genomic DNA showing K14 R125C and
242insG mutations (a, b, c) and of cloned PCR products to confirm
242insG mutation (d, e). (a) Normal keratin 14 genomic sequence
corresponding to codons 79–85 and codons 121–127. (b) The same
region of the K14 gene as shown in (a) from patient lymphocyte DNA
showing heterozygous neutral polymorphism 369C4T, N123N (arrow),
and heterozygous missense mutation 373C4T (arrow) predicting the
amino acid change R125C. (c) The same region of the K14 gene as
shown in (a) derived from patient keratinocyte genomic DNA showing
overlapping sequence due to 242insG mutation (arrow). Heterozygous
missense mutation R125C and N123N polymorphism are barely visible
(arrows). (d) The same region of the K14 gene as in (a) derived from a
clone with R125C mutation (arrow) but no 242insG mutation. (e) The
same region of the K14 gene as in (a) from a revertant clone 242insG
mutation (arrow) and R125C mutation. The 242insG mutation creates a
PTC (TAG, underlined), upstream of R125C (arrow).
Figure5
Fluorescent PCR analysis on an ABI 3100 DNA sequencer.
Heterozygous 242insG mutation was present in patient keratinocyte
genomic DNA and cDNA derived from it (c, d) but absent in control (a)
and patient lymphocyte DNA (b). Numbers correspond to the size of
PCR products in base pairs. Integration of the area under the peaks
revealed that the mutant peak in the cDNA sample is reduced by about
37% due to nonsense-mediated mRNA decay, compared to the
keratinocyte genomic DNA sample.
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protein is 81 amino acids, comprising only the V1 domain,
and from previous cases (see below) is predicted to be
nonfunctional and nonpathogenic. Staining of the keratino-
cytes with monoclonal antibody LL001 against K14 showed
a normal filament network in the majority of cells with just a
small percentage of cells having filament aggregates (Fig 2),
presumably those cells lacking the revertant mutation. Fur-
thermore, comparison of genomic PCR and RT-PCR revea-
led evidence of nonsense-mediated decay of the mRNA
species carrying the 242insG mutation (Fig 5). This would
lower the level of the truncated K14 polypeptide produced
in cells carrying the reversion mutation. This case is an exam-
ple of revertant mosaicism due to an independent frameshift
event occurring on the dominant-negative mutant allele.
In general EBS is inherited in an autosomal dominant
manner but there are several reports of recessive EBS,
caused by PTC mutations in K14 (Chan et al, 1994; Rugg
et al, 1994; Jonkman et al, 1996; Corden et al, 1998; Batta
et al, 2000; Ciubotaru et al, 2003; Lanschuetzer et al, 2003).
Homozygous individuals have a skin blistering phenotype
and complete loss of K14 expression has been demon-
strated in some of these patients; these individuals there-
fore represent human ‘‘knockouts’’ of K14 (Chan et al, 1994;
Rugg et al, 1994; Jonkman et al, 1996; Corden et al, 1998;
Batta et al, 2000; Ciubotaru et al, 2003). Heterozygous
carriers are normal with no skin phenotype. From these
cases it is predicted that the shortened forms of K14 do not
interfere with filament assembly and that one normal allele
(as present in heterozygous carriers) is sufficient to provide
a normal functioning filament network. In one case where
the truncating mutation was situated near the 30 end of the
K14 mRNA, E411X, a mutant protein including most of the
rod domain was translated in sufficient quantity to act as a
dominant-negative and lead to dominantly inherited EBS of
moderate severity (Gu et al, 2002). This is consistent with
the general finding that PTC mutations closer to the natural
stop codon lead to higher levels of protein expression
(Cooper and Krawczak, 1993). Although the 242insG mRNA
seen here is still expressed, albeit at reduced levels, the
predicted truncated protein lacks rod domain sequences
and is unlikely to exert a dominant-negative effect on keratin
assembly. This is in contrast to the majority of dominant-
acting EBS mutations where heterozygous missense or
small in-frame deletion/insertion mutations are highly dis-
ruptive to the keratin cytoskeleton. In the case presented
here, the second mutation (242insG) results in ablation of
the pathogenic R125C mutation due to an upstream PTC at
the position of the insertion. The resulting truncated K14
protein is very unlikely in the heterozygous state to interfere
with filament assembly. Thus, in this nonlesional area of the
patient’s epidermis, the allele carrying the dominant-
negative R125C mutation has been silenced by the
occurrence of a second nullifying mutation leading to the
prediction that these cells have become genetically ‘‘cor-
rected’’ by a form of ‘‘natural gene therapy’’.
There are a small number of reports of revertant
mosaicism in other skin disorders, all in recessive cases
(Jonkman et al, 1997; Darling et al, 1999; Schuilenga-Hut
et al, 2002), as well as in other genetic disorders. The
occurrence of revertants may not be as rare as one might
expect because in many cases these changes probably go
undetected as they do not revert the overall clinical pheno-
type. There are several different genetic mechanisms under-
lying revertant mosaicism including mitotic gene conversion
(Jonkman et al, 1997), splicing (Schuilenga-Hut et al, 2002),
back mutations (reverse point mutation), and second site
mutations, e.g., a frame-restoring mutation in a case of
generalized atrophic benign epidermolysis bullosa (Darling
et al, 1999). Another example of a second mutation resulting
in revertant mosaicism is in a case of recessive EBS
(Schuilenga-Hut et al, 2002). When this patient was initially
analyzed K14 expression was absent in both skin and
cultured keratinocytes and a homozygous splice site muta-
tion was identified in K14 (Jonkman et al, 1996). On re-exa-
mination of the patient, however, the authors found some
K14 expression had been restored in a mosaic pattern both
in cultured cells and in skin. This was due to a second muta-
tion but did not lead to reversion of the clinical phenotype.
Given that a relatively small number of keratinocyte cell
lines have been reported in the various forms of EB and yet
a number of cases of revertant mosaicism have been found,
it is possible that the obvious mechanical selective
advantage afforded to keratinocytes by such reversion
mutations might lead to patches of revertant epidermis in
many EB patients. In the recently developed inducible
mouse model of EBS (Cao et al, 2001), localized induced
blisters healed by re-epithelialization from the adjacent
normal epidermis where the mutation remained un-induced,
and therefore the blisters never recurred following healing.
This clearly demonstrates that keratinocytes with a normal
keratin cytoskeleton have a clear selective advantage over
those expressing a dominant keratin mutation. When one
considers the huge numbers of constantly dividing kerati-
nocytes in human epidermis, estimated at approximately
75,000 per mm2 (Bauer et al, 2001), the seemingly low
human mutation rate of approximately 2.5  10–8 per
nucleotide per generation (Nachman and Crowell, 2000)
becomes an appreciable factor. Thus, there are presumably
isolated keratinocytes in everyone’s epidermis that carry
mutations such as the revertant keratin mutation seen here.
Under suitable selective pressure, in this case blistering,
these cells can increase in numbers and in some EBS cases
may help ameliorate the skin fragility phenotype. As EBS
and other keratin disorders are known to improve with age,
as was the case with the patient studied here, it is tempting
to speculate that an accumulation of revertant mutations
might be a contributing factor to this poorly understood
phenomenon. If this proves to be true, this would have
positive implications for gene therapy in EBS and other
keratin disorders as a low level of gene correction might,
through in vivo selection, lead to a substantial improvement
in phenotype. Genetic analysis of keratinocytes derived
from older patients with EBS in whom the phenotype has
shown age-dependent improvement may shed further light
on this phenomenon.
In summary, we report the first case of revertant
mosaicism in an autosomal dominant skin disorder, which
is an example of a novel mechanism of ‘‘natural gene
therapy’’ due to the occurrence of a second nullifying
mutation. This, in addition to the other potential mechan-
isms described above, has implications for the develop-
ment of gene therapy strategies.
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Materials and Methods
All patients were seen with informed consent and all investigations
were performed with the approval of the appropriate local medical
ethics committees.
Primary keratinocyte culture A skin biopsy was taken from a
nonlesional site on the lower back. Primary keratinocytes were
cultured on mitomycin-C-treated mouse 3T3 feeder cells (Leigh
et al, 1994) in keratinocyte serum-free medium supplemented
with bovine pituitary extract and epidermal growth factor accord-
ing to the manufacturer’s protocol (Gibco InVitrogen, Paisley, UK).
Mutation detection mRNA was extracted from keratinocytes using
the QuickPrep micro mRNA purification kit (Amersham Biosciences
UK, Bucks, UK). By RT-PCR full-length K14 cDNA was amplified
with primers K14P257 50 ACC CGA GCA CCT TCT CTT CAC 30
(forward) and K14P2 50 AGT GCT TGG GCA GGA GAG GGG ATC 30
(reverse) in PCR buffer (67 mM TrisHCl, pH 8.8, 16.6 mM
(NH4)2SO4, 1.5 mM MgCl2, 0.17 mg per ml bovine serum albumin,
and 10 mM 2-mercaptoethanol). Amplification conditions were 941C
5 min  1, followed by 35 cycles of 941C 30 s, 571C 1 min, 721C
2 min, and 721C 5 min  1. PCR products were purified using
Qiagen PCR purification kit (Qiagen, Crawley, UK) and sequenced on
an ABI 3100 DNA sequencer (Applied Biosystems, Foster City CA).
Genomic DNA was extracted from peripheral blood lymphocytes
and from cultured primary keratinocytes by standard methods.
Exon 1 was amplified from lymphocyte and keratinocyte genomic
DNA using K14 specific primers K14P257 (above) and K14P35 50
TGC TGG AGA ACA AGT AGC TGC 30 (to avoid pseudogene
contamination) in PCR buffer G from PCR optimizer kit (InVitrogen).
PCR conditions were 941C 5 min  1, followed by 35 cycles of
941C 30 s, 551C 1 min, 721C 2 min, and 721C 5 min  1. PCR
products were purified using Qiagen PCR purification kit and
sequenced on an ABI 3100 DNA sequencer.
Conﬁrmation of 1 bp insertion mutation by cloning Genomic
DNA derived from the patient’s primary keratinocytes was
amplified with K14P257 and K14P35 (as above) and cloned into
pCR2.1 TA cloning vector (InVitrogen). Colonies were screened by
PCR and sequencing.
Fluorescent PCR analysis Exon 1 was amplified with primers
K14P257 and K14P35 from lymphocyte and keratinocyte genomic
DNA (as above). Nested PCR was performed on diluted PCR products
to amplify a 267 bp fragment. Primers K14ex1L 50 FAM-AGC CGC ATC
TCC TCC GTC CT 30 (forward) and K14ex1R 50 GTT TCT TTC ACT
GCC CAC CAG AAG CC C 30 (reverse) were used in 10  PCR buffer
containing 1.5 mM MgCl2 and Amplitaq Gold polymerase (Applied
Biosytems). PCR conditions were 941C 12 min  1, followed by 30
cycles of 941C 30 s, 521C 45 s, 721C 1 min, and 721C 5 min  1.
Keratinocyte cDNA was amplified directly with primers K14ex1L and
K14ex1R. Diluted PCR products were run on an AB13100 DNA
sequencer.
Immunoﬂuorescence Primary keratinocytes were grown on glass
chamber slides and fixed with methanol:acetone (1:1). The cells
were stained with monoclonal antibody LL001 to K14 (a gift from
EB Lane, University of Dundee, UK) and Alexafluor 488 goat
antimouse secondary antibody (Cambridge Bioscience, Cam-
bridge, UK). Cells were counterstained with DAPI (4,6-diamidino-
2-phenylindole, Sigma Chemicals, Poole, UK).
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